These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major.
    Author: Esposito S, D'Angelo E, Daleno C, Peia F, Scala A, Serra D, Mirra N, Galeone C, Principi N.
    Journal: Vaccine; 2010 Nov 23; 28(50):7825-8. PubMed ID: 20888873.
    Abstract:
    In order to evaluate the immunogenicity, safety, and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major, 31 subjects (19 males; mean age 17.8±8.7 years) with β-thalassemia major and 28 age- and gender-matched healthy controls were enrolled. Four weeks after vaccination, seroconversion rates were about 80% and seroprotection rates 100% in both groups. Three months after vaccination, most of the subjects remained seroconverted and the seroprotection rates were 93.5% among the patients and 100% among the controls. Safety and tolerability were also very good, with no differences between the groups.
    [Abstract] [Full Text] [Related] [New Search]